90
Participants
Start Date
October 5, 2023
Primary Completion Date
June 1, 2026
Study Completion Date
January 1, 2027
Abemaciclib
CDK4 and CDK6 inhibitor, tablet taken orally
Tamoxifen
Selective estrogen receptor modulator, taken orally per institutional standard of care
Anastrozole
Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Letrozole
Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Exemestane
Steroidal aromatase inhibitor, taken orally per institutional standard of care
LHRH Agonist
Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
Stamford Hospital, Stamford
Eastern Maine Medical Center (Northern Light), Brewer
New England Cancer Specialists, Scarborough
Boston Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute at Steward St. Elizabeth's, Brighton
Dana-Farber Cancer Institute at Foxborough, Foxborough
Dana-Farber Cancer Institute at Merrimack Valley, Methuen
Dana-Farber Cancer Institute at Milford, Milford
Dana-Farber Cancer Institute at South Shore, South Weymouth
Dana-Farber Cancer Insitute at Londonderry Hospital, Londonderry
Eli Lilly and Company
INDUSTRY
Dana-Farber Cancer Institute
OTHER